2024
Elucidating the immune active state of HR+HER2- MammaPrint High 2 early breast cancer.
Cobain E, Pusztai L, Graham C, Whitworth P, Beitsch P, Osborne C, Layeequr Rahman R, Johnson N, Brufsky A, Mahtani R, Gadi V, Hoskins K, Linden H, Mukhtar R, Esserman L, Haan J, Quinn K, Menicucci A, Audeh M, O'Shaughnessy J. Elucidating the immune active state of HR+HER2- MammaPrint High 2 early breast cancer. Journal Of Clinical Oncology 2024, 42: 506-506. DOI: 10.1200/jco.2024.42.16_suppl.506.Peer-Reviewed Original ResearchEarly-stage breast cancerAntigen presenting cellsImmune cell frequenciesImmune activation stateT cellsAntigen presentationB cellsBreast cancerResponse rate to neoadjuvant chemotherapyCell frequencyRate to neoadjuvant chemotherapyResponse rates to immunotherapyRisk of distant recurrenceCD4+ memory T cellsHigh-risk early-stage breast cancerCD8+ T cellsAntigen processingI-SPY 2Major histocompatibilityTumor-infiltrating lymphocytesMemory T cellsIncreased antigen presentationMemory B cellsActivated dendritic cellsImmune therapy response
2019
Quantitative MHC II protein expression levels in tumor epithelium to predict response to the PD1 inhibitor pembrolizumab in the I-SPY 2 Trial.
Wulfkuhle J, Yau C, Wolf D, Gallagher R, Brown Swigart L, Hirst G, Campbell M, Nanda R, Liu M, Pusztai L, Esserman L, Berry D, van 't Veer L, Petricoin E. Quantitative MHC II protein expression levels in tumor epithelium to predict response to the PD1 inhibitor pembrolizumab in the I-SPY 2 Trial. Journal Of Clinical Oncology 2019, 37: 2631-2631. DOI: 10.1200/jco.2019.37.15_suppl.2631.Peer-Reviewed Original ResearchI-SPY 2 TRIALImmune checkpoint inhibitorsCheckpoint inhibitorsTumor epitheliumPD1 inhibitor pembrolizumabTumor antigen presentationHER2-negative subtypeMHC-II expressionTumor cell expressionPredictors of responseWilcoxon rank sum testPositive associationRank sum testProtein expression levelsImmune activationControl armAntigen presentationResponse predictorsHR subgroupsB cellsCell expressionPatientsSum testProtein expressionTumors
2017
Immune gene signatures in triple-negative breast cancers characterized by varying levels of chromosomal instability.
Gyorffy B, Bottai G, Nagy A, Pusztai L, Santarpia L. Immune gene signatures in triple-negative breast cancers characterized by varying levels of chromosomal instability. Journal Of Clinical Oncology 2017, 35: 1096-1096. DOI: 10.1200/jco.2017.35.15_suppl.1096.Peer-Reviewed Original ResearchTriple-negative breast cancerCytotoxic T cellsNatural killerDendritic cellsT cellsImmune infiltrationBreast cancerTNBC samplesB cellsImmune gene signaturesOverall good prognosisKaplan-Meier analysisMann-Whitney U testChromosomal instabilityWarrants further investigationImmune infiltratesBetter prognosisTNBC patientsTNBC tumorsImmune metagenesMS tumorsImmune responseBetter survivalImmune componentsTherapeutic strategies
2012
Prognostic evaluation of the B cell/IL-8 metagene in different intrinsic breast cancer subtypes
Hanker LC, Rody A, Holtrich U, Pusztai L, Ruckhaeberle E, Liedtke C, Ahr A, Heinrich TM, Sänger N, Becker S, Karn T. Prognostic evaluation of the B cell/IL-8 metagene in different intrinsic breast cancer subtypes. Breast Cancer Research And Treatment 2012, 137: 407-416. PMID: 23242614, DOI: 10.1007/s10549-012-2356-2.Peer-Reviewed Original ResearchMeSH KeywordsB-LymphocytesBreast NeoplasmsDisease-Free SurvivalFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticHumansInterleukin-8Middle AgedOligonucleotide Array Sequence AnalysisPredictive Value of TestsPrognosisProportional Hazards ModelsReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneConceptsTriple-negative breast cancerCell/ILNegative breast cancerBreast cancer subtypesPrognostic valueBreast cancerBetter prognosisB cellsCancer subtypesIntrinsic breast cancer subtypesPrimary breast cancer samplesER-negative subtypesEvent-free survivalB cell signaturesHigher B cellsSignificant prognostic valueTriple-negative samplesBreast cancer samplesRoutine clinicopathological variablesOnly significant predictorSubtype-specific analysesTNBC subtypesClinicopathological variablesOutcome predictorsPrognostic evaluation